The United Kingdom and the United States have announced a landmark bilateral deal that will guarantee zero duties on British medicine exports being sold in the US market.
Key Provisions of the Accord
In exchange for the tariff guarantee, the UK has agreed to increase spending on drugs through the public health system. This move guarantees that duties on these key goods will stay at nothing for a duration of 36 months.
This agreement comes after previous statements to hike import taxes on patented drug products, with increases floated up to 100%.
"This agreement with the Britain bolsters the international landscape for new treatments and establishes long-overdue fairness to American-British drug exports," a statement said.
Commercial Significance
Drugs constitute one of the UK's biggest exports to the America, which is easily the primary buyer for major companies like GSK and AstraZeneca.
Trade data indicate that in the year to the end of last September, the UK sold pharmaceutical products valued at billions to the US. This figure made up a significant portion of British export trade in that period.
"This guarantee protects employment, boosts funding and facilitates the UK to become a global hub for life sciences," a government official commented.
Detailed British Pledges
The pact involves several specific commitments from the United Kingdom:
- Revised Affordability Limit: The UK will lift the price threshold at which it judges new therapies to be prohibitively costly by 25%.
- Increased NHS Spending: There is a target to raise total public funding on medicines from 0.3 percent of the national economy to 0.6 percent over the following ten-year period.
- Payback Limit: The amount manufacturers must return to the NHS to prevent overspending will be limited at fifteen percent. In the past, rebates topped 20%.
Industry Background
The pact follows a protracted tension between the pharmaceutical industry and the UK government over drug pricing and regulatory access.
The disagreement were exacerbated by arguments that American patients were charged significantly more for the equivalent treatments than patients in the other developed nations.
Recently, several significant drug company projects in the UK have been halted or scrapped, while substantial investments have been directed toward US facilities.
One official acknowledged that the NHS must invest a greater share on drugs, noting that its budget allocation on drugs had declined as a share of its resources over the last ten years.
